Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.28

+0.5%

Nov 5 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gary L. Kepler who wrote (1239)	2/8/2002 2:15:49 PM
From: tuck	Read Replies (2) of 1475

Took a little digging, but I've found the exact date at which MEDI will be discussing 507 at AAD (from AAD website): PDS 493 Tuesday, February 26 Psoriasis 7:30am-8:45am P23 Safety, Tolerance, and Disease Activity of MEDI-507 (Siplizumab) for the Treatment of Moderate to Severe Psoriasis Kim Papp, MD, PhD; Probity Medical Research, Inc, Waterloo, Canada; Richard Langley, MD; Dalhousie University, Halifax, Nova Scotia, Canada; Robert Matheson, MD; Oregon Medical Research, Portland, OR; Christine Dingivan, MD; MedImmune, Inc, Gaithersburg, MD Also presenting are competitors Abgenix (ABX-IL8), IMNX (Etanercept/Enbrel), Isis (ISIP 2302), & DNA (Efalizumab) Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next